NL-OMON37911CompletedNot Applicable
PHARMACOKINETICS AND METABOLISM OF 14C-LABELED GRC 4039 SODIUM FOLLOWING A SINGLE ORAL ADMINISTRATION IN HEALTHY MALE VOLUNTEERS - 14C-LABELED GRC 4039 SODIUM STUDY
Glenmark Pharmaceuticals SA0 sites6 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •healthy male subjects
- •18-55 yrs, inclusive
- •BMI: 18.5-29.5 kg/m2, inclusive
- •Weight: 55-95 kg, inclusive
- •non-smoking
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Investigators
Similar Trials
Completed
Not Applicable
Pharmacokinetics and metabolism of [14C] BMS-986195 in healthy male subjects10023213Rheumatoid arthritisNL-OMON44627Bristol-Myers Squibb Research and Development9
Not yet recruiting
Phase 1
Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro (Humalog) Following Single Dose Administration in Japanese Patients With Type 1 Diabetes MellitusDiabetes Mellitus, Type 1JPRN-jRCT2080223803Eli Lilly Japan K.K.
Completed
Not Applicable
Pharmacokinetics and metabolism of [14C]BMS-820836 in healthy male subjectsDepressionanxiety disorders10027946NL-OMON34571Bristol-Myers Squibb6
Active, not recruiting
Not Applicable
Therapy in combination with capecitabine, cetuximab and oxaliplatiThis study is designed as a multicentre, parallel group phase II trial with 24 first-line patients with metastatic K-ras wild type CRC. The objective of this pharmacokinetic study is to exclude a probable influence of CETUX on the plasma disposition and metabolic activation of CCB and when this regimen is given combined with OxPt.MedDRA version: 14.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002921-23-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Active, not recruiting
Not Applicable
A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degree relatives. - ALS deficiency: insulin resistance, bone strength & response to rhIGF1ALS (acid label subunit) deficiencyMedDRA version: 12.1Level: LLTClassification code 10056438Term: Growth Hormone DeficiencyEUCTR2010-019296-30-GBniversity Hospital Birmingham NHS Foundation Trust